Oral contraceptives: a cause of hyperbilirubinemia in stem cell transplant patients
| Autor: | Mary Vore, Monica Hente, Salvatore Bertolone, Lucy Fennewald, Ronald M. Kline |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Ethinyl Estradiol-Norgestrel Combination
medicine.medical_specialty Pediatrics Adolescent medicine.medical_treatment Hematopoietic stem cell transplantation Transplantation Autologous Carboplatin Oral administration Norgestrel Antineoplastic Combined Chemotherapy Protocols medicine Humans Leukemia-Lymphoma Adult T-Cell Neuroectodermal Tumors Primitive Hyperbilirubinemia business.industry Remission Induction Hematopoietic Stem Cell Transplantation Supratentorial Neoplasms Bilirubin Hematology Surgery Discontinuation Transplantation Contraceptives Oral Combined Oncology Pediatrics Perinatology and Child Health Etiology Transplant patient Female Parenteral Nutrition Total Uterine Hemorrhage Stem cell business Thiotepa medicine.drug |
| Zdroj: | Journal of pediatric hematology/oncology. 21(5) |
| ISSN: | 1077-4114 |
| Popis: | Conjugated hyperbilirubinemia in the clinical setting of hematopoietic stem cell transplantation can have multiple etiologies that may prompt various therapeutic interventions. Two patients who received short courses of a high-dose estrogen-progesterone combination to treat breakthrough menstrual bleeding during transplant are reported. Conjugated hyperbilirubinemia developed in both patients within days of beginning therapy and resolved after the ethinyl estradiol and norgestrel (Ovral; Pharmacia and Upjohn, Kalamazoo, MI, U.S.A.) was discontinued. In one of the patients, this occurred on three separate occasions during the course of transplantation. Recognizing the cholestatic effect of estrogens during transplantation may prevent unnecessary alterations in therapy beyond the simple discontinuation of these medications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|